NCT03742713 - Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions

CancerOvarian Cancer

Interventions

DRUG

CPC634 (CriPec® docetaxel)

Docetaxel containing CriPec® nanoparticles

Trial Locations (8)

Universitaire Ziekenhuizen Leuven, Leuven

CHU de Liège, Liège

University Medical Center Groningen, Groningen

Dijklander Hospital, Hoorn

Radboud University Medical Center, Nijmegen

Erasmus University Medical Center Rotterdam, Rotterdam

Viecuri Medical Center, Venlo

UCL Cancer Institute, London